Centessa

News

Eli Lilly makes $7.8bn takeover play for Centessa

Sleep disorder specialist Centessa is heading for an acquisition by Eli Lilly, which has offered $6.3bn for the US and UK-based biotech.

News

Great Britain £50 - fifty pounds sterling notes spead out.

UK biotech 'booming' as sector rakes in £1.6bn in Q2 financi...

The UK's biotechnology sector is going through a purple patch, attracting almost £1.6 billion ($2.2 billion) in financing in the three months to end-May – which is a record for the industry

News

Businessmen trading stocks online. Stock brokers looking at graphs, indexes and numbers on multiple computer screens. Colleagues in discussion in traders office. Business success concept.

Centessa plans $100m IPO to fund R&D and potential acquisiti...

Centessa has announced plans for a $100m US IPO just weeks after the company launched with $250m in private backing and an R&D powerhouse driven by the merger of 10 biotechs.

News

Slaoui exits three more companies amid harassment fallout

Moncef Slaoui has stepped down from positions at three more companies, shortly after being dismissed from a firm owned by GlaxoSmithKline for alleged sexual harassment.

News

GSK fires former R&D chief Slaoui after sexual harassment al...

GlaxoSmithKline has fired its former research boss Moncef Slaoui from the board of Galvani Bioelectronics, a company it majority owns, after an internal investigation found he sexually hara

Views & Analysis

Centessa’s founder on the new company’s unique R&D model

Putting together a quarter-billion dollar pharma company from ten mergers in four months is not for the faint-hearted – but that’s what biotech investment guru Francesco de Rubertis has ach

Eli Lilly makes $7.8bn takeover play for Centessa

UK biotech 'booming' as sector rakes in £1.6bn in Q2 financi...

Centessa plans $100m IPO to fund R&D and potential acquisiti...

Slaoui exits three more companies amid harassment fallout

GSK fires former R&D chief Slaoui after sexual harassment al...

Centessa’s founder on the new company’s unique R&D model

LSX2026: Addressing adult eye cancer, with Roi Raz

Using AI-driven synthetic personas to take your insights fur...

Centessa

Editor's Picks